Inspira Technologies is developing an “artificial lung” by directly oxygenating blood, which aims to replace the ventilator. In addition, the new technology is designed to prevent the growth of bacteria that cause sepsis. CEO Dagi Ben Nun: “Paving the way for safer and more effective treatments”
The med-tech company Inspira will develop a solution for the purpose of reducing blood infections, the company reports to the media this evening (Wednesday). This is a solution based on the development of the Ennocure MedTech company that will be incorporated into Inspira’s patent system, which prevents the growth of bacteria that cause blood contamination
The med-tech company Inspira Technologies, which develops an “artificial lung” by directly oxygenating blood and aims to replace ventilators, announces the development of technology aimed at reducing blood infections. This is a development by the med-tech company Ennocure, which will be incorporated into the INSPIRA ART systems and the Inspira patent system and aims to prevent the growth of bacteria that cause blood infection (sepsis).
The collaboration with the Inocure company was born against the background of the estimate that today in the world there are approximately 250,000 cases of blood infection per year that occur in intensive care rooms, which leads to prolonged hospitalization and increasing the costs of health services. In light of this, Inspira will integrate the technology as a means of preventing blood infections among patients who need blood oxygenation in intensive care, thus providing an effective solution to reduce complications in these processes.
Dagi Ben Noon, CEO of Inspira Technologies: “By combining our technology for direct blood oxygenation, together with Inocure’s infection prevention solutions, we are focused on potentially improving the condition of patients in intensive care and paving the way for safer and more effective treatments. This collaboration is expected to accelerate development and expand the assimilation of our technology.”
